Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference

BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. ALBO, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Paresh Soni, MD, PhD, Chief Medical Officer, is scheduled to present at the 19th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace in New York City on Monday, September 11, 2017, at 9:10 a.m. EDT.

A live audio webcast of the presentation will be accessible from the Investors page of Albireo's website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo's website for at least two weeks following the event.

For more information about the conference, visit: www.rodmanevents.com.

About Albireo 
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.   

Source: Albireo Pharma, Inc.

Investor Contact:
Hans Vitzthum                                     
LifeSci Advisors, LLC.                        
212-915-2568                                     

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com